| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.YMETH.2011.06.002 |
| P698 | PubMed publication ID | 21704168 |
| P50 | author | Felix M Mottaghy | Q89737956 |
| Boudewijn Brans | Q114516536 | ||
| P2093 | author name string | Frederik A Verburg | |
| P2860 | cites work | Impact of initial surgical treatment on survival of patients with differentiated thyroid cancer: experience of an endocrine surgery center in an iodine-deficient region | Q73093360 |
| Effects of low-iodide diet on postsurgical radioiodide ablation therapy in patients with differentiated thyroid carcinoma | Q73138058 | ||
| Follow-up of Patients with Thyroid Carcinoma | Q73709507 | ||
| Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma | Q73802829 | ||
| Fixed dosage of 131I for remnant ablation in patients with differentiated thyroid carcinoma without pre-ablative diagnostic 131I scintigraphy | Q73999598 | ||
| Papillary and Follicular Thyroid Carcinoma | Q74100773 | ||
| Redifferentiation Therapy with Retinoids: Therapeutic Option for Advanced Follicular and Papillary Thyroid Carcinoma | Q74580264 | ||
| N-linked glycosylation of the thyroid Na+/I- symporter (NIS). Implications for its secondary structure model | Q77127131 | ||
| Unilateral total lobectomy: is it sufficient surgical treatment for patients with AMES low-risk papillary thyroid carcinoma? | Q77687387 | ||
| Short-term effectiveness of low-dose radioiodune ablative treatment of thyroid remnants after thyroidectomy for differentiated thyroid cancer | Q77729546 | ||
| Historical Background of the Use of Radioactive Iodine in Medicine | Q78646234 | ||
| Serum thyroglobulin and 131I whole body scan after recombinant human TSH stimulation in the follow-up of low-risk patients with differentiated thyroid cancer | Q78815058 | ||
| Recombinant human thyrotropin-assisted radioiodine therapy for patients with metastatic thyroid cancer who could not elevate endogenous thyrotropin or be withdrawn from thyroxine | Q79378970 | ||
| Changing trends of incidence and prognosis of thyroid carcinoma in lower Franconia, Germany, from 1981-1995 | Q79884743 | ||
| Prognostic significance of successful ablation with radioiodine of differentiated thyroid cancer patients | Q81511216 | ||
| Nodal yield, morbidity, and recurrence after central neck dissection for papillary thyroid carcinoma | Q81637462 | ||
| Recombinant human thyrotropin is helpful in the follow-up and 131I therapy of patients with thyroid cancer: a report of the results and benefits using recombinant human thyrotropin in clinical routine | Q81720189 | ||
| Why radioiodine remnant ablation is right for most patients with differentiated thyroid carcinoma | Q82810268 | ||
| The absorbed dose to the blood is a better predictor of ablation success than the administered 131I activity in thyroid cancer patients | Q83139773 | ||
| Increasing incidence of thyroid cancer in the United States, 1973-2002 | Q83310394 | ||
| Cloning of the human sodium lodide symporter | Q24323256 | ||
| Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer | Q28262641 | ||
| Intraoperative monitoring of the recurrent laryngeal nerve in thyroid surgery | Q30319662 | ||
| Development and in vitro characterization of human recombinant thyrotropin | Q33655681 | ||
| The epidemiology and etiology of differentiated thyroid carcinoma | Q34034797 | ||
| Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer | Q34215677 | ||
| My career as a radioisotope hunter | Q34320502 | ||
| Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients | Q34523261 | ||
| Dosimetrically determined doses of radioiodine for the treatment of metastatic thyroid carcinoma | Q34578408 | ||
| Spatial requirement for coupling of iodotyrosine residues to form thyroid hormones | Q35049083 | ||
| The iodide trapping and binding functions of the thyroid | Q35276949 | ||
| Efficacy of low-dose iodine-131 ablation of post-operative thyroid remnants: a study of 69 cases | Q35472220 | ||
| A review of the secretion of radioactivity in human breast milk: data, quantitative analysis and recommendations. | Q35802769 | ||
| Clinical review 170: A systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer | Q35855096 | ||
| Increased incidence of thyroid carcinoma in france: a true epidemic or thyroid nodule management effects? Report from the French Thyroid Cancer Committee | Q36009325 | ||
| rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review. | Q36078981 | ||
| Thyroid stunning in vivo and in vitro | Q36185143 | ||
| European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium | Q36489842 | ||
| Second primary malignancies in thyroid cancer patients | Q36671533 | ||
| Second primary malignancy risk in thyroid cancer survivors: a systematic review and meta-analysis | Q37004650 | ||
| An updated systematic review and commentary examining the effectiveness of radioactive iodine remnant ablation in well-differentiated thyroid cancer | Q37172786 | ||
| Primary tumour diameter as a risk factor for advanced disease features of differentiated thyroid carcinoma | Q37344918 | ||
| Histology does not influence prognosis in differentiated thyroid carcinoma when accounting for age, tumour diameter, invasive growth and metastases | Q37374049 | ||
| Radioactive iodine administered for thyroid remnant ablation following recombinant human thyroid stimulating hormone preparation also has an important adjuvant therapy function | Q37699394 | ||
| Specificity of thyroid hormone synthesis The role of thyroid peroxidase | Q39187830 | ||
| Radioprotection of thyroid cells mediated by methimazole | Q39683426 | ||
| Thyroid cancer: is the incidence rise abating? | Q39860082 | ||
| Effective cancer therapy with the alpha-particle emitter [211At]astatine in a mouse model of genetically modified sodium/iodide symporter-expressing tumors | Q40314100 | ||
| Action of thiazolidinediones on differentiation, proliferation and apoptosis of normal and transformed thyrocytes in culture. | Q40411503 | ||
| A single recombinant human thyrotropin-stimulated serum thyroglobulin measurement predicts differentiated thyroid carcinoma metastases three to five years later | Q40411768 | ||
| A novel therapeutic strategy for medullary thyroid cancer based on radioiodine therapy following tissue-specific sodium iodide symporter gene expression | Q40412651 | ||
| Radioiodine therapy of colon cancer following tissue-specific sodium iodide symporter gene transfer | Q40498934 | ||
| Management of the patient with progressive radioiodine non-responsive disease | Q40828601 | ||
| Pendrin, the protein encoded by the Pendred syndrome gene (PDS), is an apical porter of iodide in the thyroid and is regulated by thyroglobulin in FRTL-5 cells | Q40903949 | ||
| Regulation by thyroid-stimulating hormone of sodium/iodide symporter gene expression and protein levels in FRTL-5 cells | Q41108571 | ||
| Low iodine diet in I-131 ablation of thyroid remnants. | Q42464889 | ||
| Analysis of the thyroglobulin internalization process using in vitro reconstituted thyroid follicles: evidence for a coated vesicle-dependent endocytic pathway | Q42473172 | ||
| A comparison of 1850 (50 mCi) and 3700 MBq (100 mCi) 131-iodine administered doses for recombinant thyrotropin-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer | Q42515151 | ||
| Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. | Q43016588 | ||
| Quality of life and effectiveness comparisons of thyroxine withdrawal, triiodothyronine withdrawal, and recombinant thyroid-stimulating hormone administration for low-dose radioiodine remnant ablation of differentiated thyroid carcinoma. | Q43164014 | ||
| Optimized 124I PET dosimetry protocol for radioiodine therapy of differentiated thyroid cancer | Q43501303 | ||
| A new cause of renal thrombotic microangiopathy: yttrium 90-DOTATOC internal radiotherapy | Q43556365 | ||
| Impact of primary surgery on outcome in 300 patients with pathologic tumor-node-metastasis stage III papillary thyroid carcinoma treated at one institution from 1940 through 1989. | Q43583286 | ||
| [177Lu-DOTA(0),Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy | Q43599636 | ||
| Radiopeptide transmitted internal irradiation of non-iodophil thyroid cancer and conventionally untreatable medullary thyroid cancer using | Q43637635 | ||
| Health-related quality-of-life study in patients with carcinoma of the thyroid after thyroxine withdrawal for whole body scanning | Q43735640 | ||
| Low-iodine diet in the treatment of differentiated thyroid cancer with radioactive iodine | Q44012923 | ||
| Targeted radioiodine therapy of neuroblastoma tumors following systemic nonviral delivery of the sodium iodide symporter gene | Q44128252 | ||
| Tumour dosimetry and response in patients with metastatic differentiated thyroid cancer using recombinant human thyrotropin before radioiodine therapy | Q44360536 | ||
| Recombinant human TSH-aided radioiodine treatment of advanced differentiated thyroid carcinoma: a single-centre study of 54 patients | Q44463388 | ||
| Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation | Q44582444 | ||
| Reevaluation of the impact of a stringent low-iodine diet on ablation rates in radioiodine treatment of thyroid carcinoma | Q44612895 | ||
| Papillary and follicular thyroid cancer: impact of treatment in 1578 patients | Q44744571 | ||
| Multivariate analysis of risk factors for postoperative complications in benign goiter surgery: prospective multicenter study in Germany | Q44816664 | ||
| Receptor radionuclide therapy with 90Y-DOTATOC in patients with medullary thyroid carcinomas. | Q44833426 | ||
| Rapid rise in serum thyrotropin concentrations after thyroidectomy or withdrawal of suppressive thyroxine therapy in preparation for radioactive iodine administration to patients with differentiated thyroid cancer | Q44968751 | ||
| Establishment of radioactive astatine and iodine uptake in cancer cell lines expressing the human sodium/iodide symporter | Q45887732 | ||
| Complications of neck dissection for thyroid cancer | Q46082697 | ||
| Value of diagnostic radioiodine scintigraphy and thyroglobulin measurements after rhTSH injection. | Q46124192 | ||
| Low-activity (2.0 GBq; 54 mCi) radioiodine post-surgical remnant ablation in thyroid cancer: comparison between hormone withdrawal and use of rhTSH in low-risk patients | Q46202467 | ||
| Thyroid Na+/I- symporter. Mechanism, stoichiometry, and specificity | Q46213441 | ||
| Rosiglitazone effect on radioiodine uptake in thyroid carcinoma patients with high thyroglobulin but negative total body scan: a correlation with the expression of peroxisome proliferator-activated receptor-gamma. | Q46481111 | ||
| Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival | Q46619794 | ||
| Children with differentiated thyroid cancer achieve adequate hyperthyrotropinemia within 14 days of levothyroxine withdrawal | Q46642985 | ||
| Thyroid hormone withdrawal in patients with differentiated thyroid carcinoma: a one hundred thirty-patient pilot survey on consequences of hypothyroidism and a pharmacoeconomic comparison to recombinant thyrotropin administration | Q46798198 | ||
| A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal | Q46880174 | ||
| The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer. | Q47570668 | ||
| Comparison of radioiodine biokinetics following the administration of recombinant human thyroid stimulating hormone and after thyroid hormone withdrawal in thyroid carcinoma | Q47765924 | ||
| Compliance with follow-up and the informative value of diagnostic whole-body scan in patients with differentiated thyroid carcinoma given recombinant human TSH. | Q47973787 | ||
| Dosimetry-guided high-activity (131)I therapy in patients with advanced differentiated thyroid carcinoma: initial experience | Q50589541 | ||
| Outcome after treatment of high-risk papillary and non-Hürthle-cell follicular thyroid carcinoma | Q50860942 | ||
| Iodine-124 PET dosimetry in differentiated thyroid cancer: recovery coefficient in 2D and 3D modes for PET(/CT) systems | Q50892441 | ||
| Quality-of-Life Changes in Patients with Thyroid Cancer After Withdrawal of Thyroid Hormone Therapy | Q51101509 | ||
| Recombinant thyrotropin use in children and adolescents with differentiated thyroid cancer: a multicenter retrospective study. | Q51613326 | ||
| Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal | Q51706409 | ||
| The incidence of second primary tumors in thyroid cancer patients is increased, but not related to treatment of thyroid cancer | Q51775246 | ||
| No survival difference after successful (131)I ablation between patients with initially low-risk and high-risk differentiated thyroid cancer | Q51788283 | ||
| EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry I: blood and bone marrow dosimetry in differentiated thyroid cancer therapy | Q51956739 | ||
| Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study | Q53263951 | ||
| Independent clonal origins of distinct tumor foci in multifocal papillary thyroid carcinoma | Q53671821 | ||
| Radioactive iodine therapy; effect on functioning metastases of adenocarcinoma of the thyroid | Q53768649 | ||
| Identification and Characterization of a Putative Human Iodide Transporter Located at the Apical Membrane of Thyrocytes | Q56592887 | ||
| Guidelines for radioiodine therapy of differentiated thyroid cancer | Q57482620 | ||
| A Comparison of Recombinant Human Thyrotropin and Thyroid Hormone Withdrawal for the Detection of Thyroid Remnant or Cancer | Q58004661 | ||
| Radiation-Induced Thyroid Stunning: Differential Effects of 123I, 131I, 99mTc, and 211At on Iodide Transport and NIS mRNA Expression in Cultured Thyroid Cells | Q58353948 | ||
| The diagnostic use of the rhTSH/thyroglobulin test in differentiated thyroid cancer patients with persistent disease and low thyroglobulin levels | Q63346836 | ||
| Failure of low doses of 131I to ablate residual thyroid tissue following surgery for thyroid cancer. | Q64895924 | ||
| The incidence of bilateral well-differentiated thyroid cancer found at completion thyroidectomy | Q67565985 | ||
| Long-term results and prognostic factors in patients with differentiated thyroid carcinoma | Q70048752 | ||
| Comparison of 30- and 50-mCi doses of iodine-131 for thyroid ablation | Q70264985 | ||
| Thyroidal Thyronine and Non-Thyronine Iodine Secretion in Euthyroid Subjects | Q70532129 | ||
| Kinetics of Thyroglobulin Iodination and Thyroid Hormone Synthesis Catalyzed by Peroxidases: The Role of H2O2 | Q70870570 | ||
| Prospective randomized clinical trial to evaluate the optimal dose of 131 I for remnant ablation in patients with differentiated thyroid carcinoma | Q71102237 | ||
| Moderate hypothyroidism in preparation for whole body 131I scintiscans and thyroglobulin testing | Q71331618 | ||
| Thyroglobulin measurement and postablative iodine-131 total body scan after total thyroidectomy for differentiated thyroid carcinoma in patients with no evidence of disease | Q71398741 | ||
| Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer | Q72849361 | ||
| Radiotherapy with a radiolabeled somatostatin analogue, [111In-DTPA-D-Phe1]-octreotide. A case history | Q72853202 | ||
| P433 | issue | 3 | |
| P304 | page(s) | 230-237 | |
| P577 | publication date | 2011-06-16 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Methods | Q6823859 |
| P1476 | title | Molecular nuclear therapies for thyroid carcinoma | |
| P478 | volume | 55 |
| Q35804494 | Calibration of Traceable Solid Mock (131)I Phantoms Used in an International SPECT Image Quantification Comparison. |
| Q51652256 | Current and future aspects of nuclear molecular therapies: A model of theranostics |
| Q55332109 | Does the use of recombinant TSH in preparation for I-131 scintigraphy scan affect hearing function? |
| Q92545587 | Iodine‑131 metabolic radiotherapy leads to cell death and genomic alterations through NIS overexpression on cholangiocarcinoma |
| Q35915781 | Sodium Iodide Symporter for Nuclear Molecular Imaging and Gene Therapy: From Bedside to Bench and Back |
| Q93016071 | Targeting uptake transporters for cancer imaging and treatment |
Search more.